ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Southern Swedish company Aqilion develops drug for eosinophilic esophagitis

When Aqilion began developing a drug for eosinophilic esophagitis, the molecule was classified as an orphan drug. But the prevalence of the disease now appears ...

GU Ventures AB

Mercodia AB

Efter förseningen – nu lämnar Xspray in uppdaterad FDA-ansökan

Forskningsbolaget Xspray Pharma har nu lämnat in en uppdaterad FDA-ansökan om godkännande för leukemibehandlingen Dasynoc.

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...

An organ seldom in the spotlight – but utterly vital

The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclin...

Lifs Sofia Wallström tar plats i EFPIA:s styrelse

Lifs vd Sofia Wallström har valts in i styrelsen för den europeiska branschorganisationen EFPIA.

Shaping regulatory complexity into strategic clarity

As AI continues to reshape healthcare, clear guidance on health data use is more critical than ever. Building on the success of the AI Act e-tool and the Data A...

Milstolpe nådd för Leqembi – Bioarctic kan casha in

Försäljningen av alzheimerläkemedlet Leqembi har nått sin första milstolpe, och därmed kan svenska Bioarctic på allvar börja skörda frukterna av sitt utvecklingsarbete.

Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

Merck investerar över 70 miljarder dollar i USA

Merck & Co följer flera andra globala läkemedelsjättar och pumpar in hundratals miljarder kronor i nya produktionsanläggningar i USA.

Chiesi satsar på leverinriktad genterapi

Läkemedelsbolaget Chiesi tar ytterligare kliv in på genterapiområdet genom ett licensavtal med amerikanska Arbor Biotechnologies.

Agreement in the EU on eight years of data exclusivity for new medicines

New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...

Organize and Manage Digital Classrooms

Create engaging lessons with ZEISS Labscope Teacher.

Bico säljer bolag inom in vitro-testning och digital patologi

Bioteknikbolaget Bico avyttrar Mattek och Visikol, som integrerades i Mattek operationellt förra året, till Sartorius Lab. Köpeskillingen är på 80 miljoner doll...

Ranking: Top 10 highest-paid CEOs in pharma

It's nice to hear that things go well for others, right? Some of those who have done really well – at least financially – are listed here in the ranking of the ...

A cluster contribution to European life science innovation and competitiveness?

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

Radiofarmakabolaget Aktis tar in miljardbelopp

Amerikanska biotechbolaget Aktis Oncology, som utvecklar radiofarmaka, tar in 175 miljoner amerikanska dollar, motsvarande cirka 1,8 miljarder svenska kronor, g...

Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow

Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.